Assessing the value-adding impact of diagnostic-type tests on drug development and marketing

Molecular Diagnosis and Therapy

Volumn 12, Issue 5, 2008, Pages 331-337

  Blair, Edward D ^a  

^a Integrated Medicines Ltd   (United Kingdom)

Author keywords

Diagnostic Tests; Diagnostics; Research and development

Indexed keywords

ARTICLE; COMPUTER ANALYSIS; DIAGNOSTIC TEST; DRUG INDUSTRY; DRUG MARKETING; FINANCIAL MANAGEMENT; PRIORITY JOURNAL;

NUCLEOPOLYHEDROVIRUS;

EID: 52449133413     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256298     Document Type: Article

References (38)

1. Glaxo Smithkline to be formed in £114bn "merger of equals". Pharm J 2000 Jan 22; 264 (7080): 125 [online]. Available from URL: http://www.pharmj.com/Editorial/20000122/business/glaxosmithkline.html [Accessed 2008 Aug 11]
2. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007; 6: 287-93
3. Belsey MJ. Drug developers strategies to boost competitiveness. Nat Rev Drug Discov 2007; 6: 265-6
4. Orenstein BW. Visions of the future of IVDs. IVDT News 2007; 9: 43-7 [online]. Available from URL: http://www.devicelink.com/ivdt/archive/07/09/010. html [Accessed 2008 Aug 11]
5. Beyond the pill. The Economist 2007 Oct 25 [online]. Available from URL: http://www.economist.com/business/displaystory.cfm?story_id=10026788 [Accessed 2008 Aug 11]
6. A dream team of drugs and diagnosis? BusinessWeek 2007 Oct 1 [online]. Available from URL: http://www.businessweek.com/magazine/content/07_40/b4052064. htm [Accessed 2008 Aug 11]
7. US Food and Drug Administration homepage [online]. Available from URL: http://www.fda.gov/ [Accessed 2007 Oct 11]
8. Tsuchiya T. Provisions for review of genetic research in Japan. Eubios J Asian Int Bioethics 2003; 13: 127-30
9. European Medicines Agency homepage [online]. Available from URL: http://www.emea.europa.eu/ [Accessed 2007 Oct 11]
10. Rutterford J, Upton M, Kodwani D, editors. Financial strategy. 2nd ed. Chichester: Wiley & Sons, 2006
11. DiMasi JA, Grabowski HG, Vernon J. R&D costs and returns by therapeutic category. Drug Inf J 2004; 38: 211-23
12. DiMasi JA. Tufts CSDD quantifies savings from boosting new drug R&D efficiency. Tufts CSDD Impact Rpt 2002; 4 (5): 1-4 [online]. Available from URL: http://csdd.tufts.edu/InfoServices/ImpactReportPDFs/ImpRptOct2002.pdf [Accessed 2008 Aug 11]
13. Kleine J. Is personalised medicine getting closer? IMS Health Commentary [online]. Available from URL: http://www1.imshealth.com/web/content/0,3148, 73767110_63872702_70515404_80066048,00.html [Accessed 2007 Oct 11]
14. Reichert R. Cambridge Pharma Consultancy, 2004; Data on file
15. Sherner A, Simon M, Williams J. Generic competition. PriceWaterHouse Cooper [online]. Available from URL: http://www.pwc.com/extweb/industry.nsf/ docid/004B5431685B1EEC852570A8007B5345 [Accessed 2007 Oct 11]
16. Bulter R. Patent life-cycle: Richard Butler explains how a drug's life cycle management is becoming a part of drug development [online]. Available from URL: http://goliath.ecnext.com/coms2/summary_0199-326508_ITM [Accessed 2007 Oct 11]
17. MarketResearch.com. Lifecycle management strategies: maximizing ROI through indication expansion, reformulation and Rx-to-OTC switching [online]. Available from URL: http://www.marketresearch.com/product/display.asp?productid= 1259423&g=1 [Accessed 2007 Oct 11]
18. IBM Pharma Consulting. Pharma 2010: the threshold of innovation [online]. Available from URL: http://www-935.ibm.com/services/us/index.wss/ibv-study/imc/ a1001099?cntxt=a1000060 [Accessed 2007 Oct 15]
19. Arnold K, Coia A, Saywell S, et al. Value drivers in licencing. Nat Biotechnol 2002; 20: 1085-9
20. Gilham I. Theranostics: an emerging tool in drug discovery and commercialisation. Drug Discov World 2002; 1 (3): 17-23
21. Pharmapredict [online]. Available from URL: http://www.pjbpubs.com/ pharmapredict/index.htm [Accessed 2008 Aug 11]
22. EvaluatePharma [online]. Available from URL: http://www.evaluatepharma. com/ [Accessed 2008 Aug 11]
23. Little S, Blair ED. Pharmacodiagnostics: technologies, competition, and market models. Insight Pharma Reports 2005 Jul [online]. Available from URL: http://www.insightpharmareports.com/reports/2005/51_Pharmacodiagnostics/ overview.asp [Accessed 2008 Aug 11]
24. Research and Markets. A guide to royalty rates in pharmaceutical licensing deals [online]. Available from URL: http://www.researchandmarkets.com/ reports/c71991 [Accessed 2007 Oct 15]
25. Largen M. Trends in the commercialization of biomarkers: tests and companies. Spectrum 2007 Oct [online]. Available from URL: http://www. decisionresources.com/stellent/groups/public/documents/abstract/07h306-abstract. hcsp [Accessed 2007 Oct 15]
26. Abrahams E, editor. The case for personalized medicine. The Personalized Medicine Coalition. 2006 Nov [online]. Available from URL: http://www. personalizedmedicinecoalition.org/communications/pmc_pub_11_06.php [Accessed 2007 Oct 11]
27. Pfizer's AIDS drug wins us approval: monogram biosciences launches diagnostic test [online]. Available from URL: http://www.pharmaweek.com/TopNews/ Maraviroc.asp [Accessed 2007 Oct 15]
28. Celera. Celera enters oncology research collaboration with Merck to develop pharmacogenomic tests. 2007 Sep 17 [press release; online]. Available from URL: http://www.celera.com/celera/pr_1190030438 [Accessed 2007 Oct 15]
29. National Institute for Health and Clinical Excellence. 2007/018 NICE recommends a scheme to make bortezomib (Velcade) for multiple myeloma accessible to NHS patients [online]. Available from URL: http://www.nice.org.uk/page.aspx? o=433063 [Accessed 2007 Oct 15]
30. Hughes B. Novel risk-sharing scheme puts the spotlight on biomarkers. Nat Rev Drug Discov 2007; 6: 945
31. Blair ED, Stocum M, Stephens EA. Personalized medicines: time to close the talking-shop? Third Annual Burrill Personalized Medicine Meeting; 2007 Nov 12-13; San Francisco
32. Allison M. Is personalized medicine finally arriving? Nat Biotechnol 2008; 26: 509-17
33. Deverka PA, Doksum T, Carlson RJ. Integrating molecular medicine into the US healthcare system: opportunities, barriers and policy challenges. Clin Pharmacol Ther 2007; 82: 427-34
34. Jones D. Steps on the road to personalized medicine. Nat Rev Drug Discov 2007; 6: 770-1
35. Johnson S. Hazy future for genetic drugs, tests: insurance fears limit treatments on market [online]. Available from URL: http://www.siliconvalley.com/ ci_4936266?nclick_check=1 [Accessed 2008 Aug 12]
36. Pickering L. Companion diagnostics: enabling personalized medicines in cancer. Spectrum Reports [online]. Available from URL: http://www. researchandmarkets.com/reports/357191 [Accessed 2007 Oct 15]
37. The Royal Society. Personalised medicines: hopes and realities [online]. Available from URL: http://royalsociety.org/displaypagedoc.asp?id=15874 [Accessed 2007 Oct 11]
38. Gregson N, Sparrowhawk K, Mauskopf J, et al. Pricing medicines: theory and practice, challenges and opportunities. Nat Rev Drug Discov 2005; 4: 121-30